Please login to the form below

Not currently logged in
Email:
Password:

Acambis patent boost

Transcripts reveal that ITC could come down on side of UK firm in dispute over smallpox vaccine

Shares in Acambis received a boost after lawyers from the US International Trade Commission (ITC) appeared to back the UK vaccine maker in its dispute with Danish rival, Bavarian Nordic, over patents for a smallpox vaccine.

The ITC released transcripts of the public sessions of a hearing on the case concerning the vaccine, called MVA.

Analyst Jonathan Senior at Evolution Securities told Reuters that although the ITC was yet to make a judgment, in its opening statement it had come down on the side of Acambis, saying the firm ìdidn't have a case to answerî.

ìThey're saying Bavarian Nordic's patents are not valid,î he said.

Acambis and Bavarian Nordic are fiercely competing for a lucrative US government contract to supply the vaccine.

In May, Acambis and US marketing partner Baxter, which manufactures the MVA vaccine, MVA3000, in Austria, filed opposition to a European patent granted to Bavarian Nordic regarding a weakened form of the vaccine, targeted at those who are immunocompromised, including those with HIV. Bavarian Nordic had claimed the two companies would be infringing its patents if they sell their smallpox vaccine to the US government.

ITC lawyers, acting as a third party, have told the ITC judge that Bavarian Nordic's patents are invalid and also unenforceable.

The ITC judge's initial determination on the case is expected around the end of August.

30th September 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Red Health

Red Health was formed in 2007 to bring something fresh to the healthcare PR world. Our approach was simple –...

Latest intelligence

Empowered patients: shaking the foundations of healthcare
Precision medicine represents a new paradigm in healthcare.This new approach to treating and preventing disease views the patient holistically, analysing their genes, environment and lifestyle, and using this information to...
A uniquely English genomic medicine service
The UK National Health Service is developing one standardised approach to embedding precision medicine across the whole of England. Blue Latitude Health speaks to Dr Tom Fowler, Deputy Chief Scientist...
Blended Intelligence
Data is the most valued commodity of the modern world. For P&P it's all about the application....

Infographics